Breast Cancer breakthroughs at London's Toby Robins Research Centre

Experts including Prof Lord reveal that a new class of drugs, called PARP inhibitors, work especially well against cancer cells with altered BRCA genes, while leaving healthy cells intact.

- 

Aromatase inhibitors are approved to treat early postmenopausal breast cancer on the NHS.

They show this hormone therapy works better than existing treatments to stop breast cancer coming back.

The Triple Negative Trial begins. It looks at whether carboplatin chemotherapy is more effective than docetaxel for some people with secondary triple negative breast cancer. Over 10 years later, it leads to a change in treatment guidelines.

Researchers create a promising new test called IHC4 to identify which people with hormone-sensitive breast cancer will benefit from chemotherapy.